Abzena PLC Fundamentals Datasheet and Stock Analysis


Abzena PLC Company Logo
Abzena plc is a life sciences company. The Company provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups. It offers immunogenicity assessment, which includes EpiScreen, iTope and T Cell Epitope Database (TCED); antibody drug conjugates, which includes ThioBridge linkers; antibody, which includes Composite Human Antibodies and Composite Proteins; optimization of pharmacokinetics, which includes TheraPEG, HiPEG conjugates PEG to poly-histidine motifs and CyPEG, and PolyPEG; cell line development, which includes Composite Human Antibody; process development, Good manufacturing practices (GMP) manufacturing, and small molecules. The Company's Abzena inside includes Composite Human Antibodies and ThioBridge Antibody Drug Conjugates (ADCs).

  • Current Price:
  • Industry:
     Health Care
  • Sector:
     Health Care
  • ISIN:
  • Market Sector:
  • Main Indices:
  • Country of register:
     Great Britain
  • Currency:
  • Shares in Issue:
  • Market Cap:
  • Date Listed:
Operation Breakdown
Geographical - by origin (turnover)
Product (turnover)


Activity Data Not Available

Company Information

CEO: John Burt  CFO: Julian Smith  Chairman: Ken Cunningham  Non-Executive Director: Peter Grant, Anthony Brampton, Nigel Pitchford Lotta Ljungqvist  Chief Business Officer: Sven Lee  

  • Registrars:
  • Address:
     Babraham Research Campus, Babraham, Cambridge, United Kingdom
  • Phone:
  • Website:
Composite Ranking: 52
Historic EPS Ranking: 52
Forecast EPS Ranking: 19
Price Relative Strength: 8
Industry Strength: E
SMR Ranking: A
ROCE Ranking: F
Mkt Accumulation/Dist: C
Unbroken Annual EPS: E
Unbroken Interim EPS: E
PEG Current Ranking: A
PEG Forecast Ranking: A
PE Current Ranking: A
PE Forecast Ranking: A
Margin Current Ranking: H
Margin Forecast Ranking: G
Add Indicator


Takes the average of data over a period of time, and migrates the period across the data series one data point at a time. This formula smooths a data series and makes analysing volatile data easier.
Operating Profit/(loss)£m(4.12)(5.30)10.90(9.74)£m0.000.000.00
Profit Before Tax£m(4.10)(5.22)(10.66)(9.46)£m(15.07)(12.10)(7.58)
Profit After Tax£m(3.55)(4.72)(9.70)(9.12)£m0.000.000.00
Profit After Tax (from discontinued operations)£m0.£m0.000.000.00
Overall Profit for the Period£m(3.55)(4.72)(9.70)(9.12)£m0.000.000.00
EPS Growth%
Earnings Per Sharep(253.00)(7.00)(9.00)(7.00)p(7.57)(6.68)(3.32)
Op. Cash Flow P/Sp0.£
Cash Flow P/S Grth%
Net Cash Flow P/Sp0.£
Capital Exp P/S££
Tax Rate%
P/E Ratiox0.
P/E Growth££
Turnover Per Share££
Pre-Tax Profit / Share££
Operating Margin%(78.39)(93.47)110.66(52.23)%
Mkt Cap£m0.00179.95107.1180.33£m0.000.000.00
Dividend Per Sharep0.
DPS Growth%
Dividend Yield%
Dividend Coverx0.
Shareholder Funds£m13.5327.8541.0635.93£m0.000.000.00
Net Borrowings£m(2.76)(15.80)(13.72)(4.13)£m0.000.000.00
Net Assets£m13.5327.8541.0635.93£m0.000.000.00
Net Assets P/S££
Latest Forecast
Div Yield0.0%0.0%
Div Cover0.0%0.0%
Op Margin-52.2%-41.4%
Director Deals
Traded Action Notifier Price Amount Value
10-Apr-17Transfer ToPeter Grant33.00p 25,000£8,250
16-Aug-16Exercise of optionAnker Lundemose0.02p 75,000£15
27-Jun-16Transfer ToJohn Burt41.00p 98,000£40,180
  Rows per page
214m    Major: 76%    Director: 1%
Notifier Holding Value
John Burt2,120,262413,451.09
Julian Smith262,08451,106.38
Peter Grant58,30311,369.08
  Rows per page
Gearing & Cover
Broker Opinion
Date Broker Name Rec Price Old Price Target New Price Target Broker Change
08-Jun-15N 1 SingerBuy86.00p0.00p0.00pReiteration
  Rows per page

This functionality requires you to login

Click here to login
Or register for a new account